Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-08-02
2011-08-02
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S009200, C435S007100, C435S007200, C530S300000, C530S350000, C536S023100, C536S023700
Reexamination Certificate
active
07988980
ABSTRACT:
The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
REFERENCES:
patent: 6673353 (2004-01-01), Kaufmann et al.
patent: WO 99/10496 (1999-03-01), None
Kremer, L., et al. Infection and Immunity, vol. 68, No. 7, pp. 4264-4273, Jul. 2000.
Guenounou, M. Immuno-Analyse et Biologie Specialisee, vol. 12, No. 2, pp. 65-69, May 1997.
Eun-Kyeong, J. Current Opinion in Infectious Diseases, vol. 16, No. 3, pp. 205-210, 2003.
Fujiwara, R.T., et al. PLoS Neglected Tropical Diseases, vol. 3, No. 3, article e399, Mar. 2009.
Zhong, J. European Journal of Immunology, vol. 38, No. 1, pp. 73-81, Jan. 2008.
Hess et al., “Mycobacterium bovis bacille Calmette-Guérin strains secreting listeriolysin of lysteria monocytogenes”, Proceedings of the National Academy of Sciences of USA, vol. 95, Apr. 1, 1998, pp. 5299-5304.
Reyrat et al., “Urease activity does not contribute dramatically to persistence of Mycobacterium bovis bacillius Calmette-Guerin”, Infection and Immunity, vol. 64, No. 9, 1996, pp. 3934-3936.
Reyrat et al., “The urease locus of Mycobacterium tuberculosis and its utilization for the demonstration of allelic exchange in Mycobacterium bovis bacillus Calmette-Guerin”, Proceedings of the National Academy of Sciences of The United States of America, vol. 92, No. 19, 1995, pp. 8768-8772.
Clemens et al., “Purification characterization and genetic analysis of Mycobacterium tuberculosis urease, a potentially critical determinant of host-pathogen interaction”, J.Bacteriology, vol. 177, No. 19, 1995, pp. 5644-5652.
Guleria et al., “Auxotrophic vaccines for tuberculosis”, Nature Medicine, vol. 2, No. 3, Mar. 1996, pp. 334-337.
Nagy et al., Effect of perfringolysin O on the lateral diffusion constant of membrane proteins of hepatocytes as revealed by fluorescence recovery after photobleaching., Biochim Biophys Acta., 1988, 939(3), 551-560.
Awad and Rood, Perfringolysin O expression inClostridium perfringensis independent of the upstream pfoR gene., Journal of Bacteriology, 2002, 184(7), 2034-2038.
Grode et al., “Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin”, The Journal of Clinical Investigation, vol. 115, No. 9, Sep. 2005, pp. 2472-2479.
Jones et al., “Characterization of Listeria monocytogenes Pathogenesis in a Strain Expressing Perfringolysin O in Place of Listeriolysin O in Place of Listeriolysin O”, Infection and Immunity, Dec. 1994, p. 5608-5613.
Portnoy et al., Capacity of Listeriolysin O, Streptolysin O, and Perfringolysin O to Mediate Growth of Bacillus subtilis within Mammalian Cells, Infection and Immunity, vol. 60, No. 7, Jul. 1992, p. 2710-2717.
Sambrook et al., Molecular Cloning, A laboratory Manual. Cold Spring Harbor Laboratory Press (1989), 1.101-1.104.
Grode Leander
Hess Jürgen
Kaufmann Stefan H. E.
Raupach Bärbel
Max-Planck-Gesellschaft zur Foerderung Der Wissenshaften e. V.
Rothwell Figg Ernst & Manbeck P.C.
Swartz Rodney P.
LandOfFree
Tuberculosis vaccine with improved efficacy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tuberculosis vaccine with improved efficacy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tuberculosis vaccine with improved efficacy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2634132